Oene Mark Van Sells 129,790 Shares of Pacific Biosciences of California (NASDAQ:PACB) Stock

Pacific Biosciences of California, Inc. (NASDAQ:PACB) insider Oene Mark Van sold 129,790 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $1.58, for a total value of $205,068.20. Following the sale, the insider owned 1,797,745 shares of the company’s stock, valued at $2,840,437.10. This represents a 6.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Oene Mark Van also recently made the following trade(s):

• On Wednesday, February 18th, Oene Mark Van sold 55,107 shares of Pacific Biosciences of California stock. The stock was sold at an average price of $1.63, for a total value of $89,824.41.

Pacific Biosciences of California Trading Down 4.2%

Shares of PACB opened at $1.61 on Friday. Pacific Biosciences of California, Inc. has a one year low of $0.85 and a one year high of $2.73. The stock has a 50-day moving average price of $2.01 and a 200 day moving average price of $1.78. The company has a debt-to-equity ratio of 17.88, a quick ratio of 5.40 and a current ratio of 6.24. The company has a market capitalization of $486.08 million, a P/E ratio of -0.87 and a beta of 2.27.

Pacific Biosciences of California (NASDAQ:PACB) last announced its earnings results on Thursday, February 12th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. Pacific Biosciences of California had a negative return on equity of 251.75% and a negative net margin of 341.47%.The company had revenue of $44.65 million for the quarter, compared to analyst estimates of $44.60 million. Sell-side analysts forecast that Pacific Biosciences of California, Inc. will post -0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Pacific Biosciences of California

A number of hedge funds and other institutional investors have recently bought and sold shares of PACB. Koss Olinger Consulting LLC raised its position in shares of Pacific Biosciences of California by 10.0% during the 2nd quarter. Koss Olinger Consulting LLC now owns 3,300,000 shares of the biotechnology company’s stock worth $4,092,000 after purchasing an additional 300,000 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in Pacific Biosciences of California by 148.1% during the 2nd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 789,271 shares of the biotechnology company’s stock worth $979,000 after buying an additional 471,101 shares during the last quarter. Carret Asset Management LLC acquired a new stake in Pacific Biosciences of California in the second quarter worth $391,000. Vestmark Advisory Solutions Inc. lifted its stake in Pacific Biosciences of California by 89.9% in the second quarter. Vestmark Advisory Solutions Inc. now owns 1,294,186 shares of the biotechnology company’s stock valued at $1,605,000 after buying an additional 612,760 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Pacific Biosciences of California by 6.4% in the second quarter. Geode Capital Management LLC now owns 6,718,879 shares of the biotechnology company’s stock valued at $8,333,000 after buying an additional 401,637 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on PACB shares. Stephens boosted their target price on shares of Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an “overweight” rating in a research report on Monday, November 10th. Piper Sandler boosted their price objective on Pacific Biosciences of California from $1.50 to $2.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Barclays upped their price objective on Pacific Biosciences of California from $1.50 to $2.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pacific Biosciences of California currently has a consensus rating of “Hold” and an average target price of $2.20.

Key Pacific Biosciences of California News

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: Genomics sector tailwind — Zacks published a roundup arguing genomics and synthetic-biology stocks deserve portfolio consideration in 2026, supporting longer‑term demand for sequencing platforms like PacBio’s systems. Genomics Stocks That Deserve a Place in Your Portfolio in 2026
• Positive Sentiment: Institutional accumulation — Large funds (ARK, Millennium, Renaissance, Casdin) materially increased or initiated PACB positions in recent quarters, which can provide liquidity support and signal conviction from some professional investors. MarketBeat PACB institutional holdings
• Neutral Sentiment: Upcoming investor event — PacBio will present at the TD Cowen Health Care Conference on March 2; management commentary there could provide updated commercialization or adoption metrics but nothing material has been released yet. PacBio at TD Cowen Conference
• Neutral Sentiment: Analyst mix — Recent notes show modest price‑target upgrades to ~$2.00 from some shops while consensus remains “Hold” with an average PT ~ $2.20; mixed coverage limits a catalytic analyst push. PACB analyst coverage
• Negative Sentiment: Large insider selling — Director/insider Christian O. Henry sold ~472,667 shares across Feb. 17–18 (~$753k proceeds). High‑profile insider sales at this scale often pressure the stock. Christian O. Henry Form 4
• Negative Sentiment: Additional insider exits — Oene Mark Van sold ~184,897 shares (Feb. 17–18) and Michele Farmer sold ~50,167 shares (Feb. 17–18); the combined insider reductions may amplify negative sentiment short‑term. Oene Mark Van Form 4 Michele Farmer Form 4

About Pacific Biosciences of California

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.